2023年7月3日

Cerecin给tricaprilin发现二期试验研究结果显示,治疗偏头痛可能受益的经历。研究结果显示,Cerecin tricaprilin可能受益的那些经历偏头痛。Cerecin生物技术公司开发神经病治疗已经从最近的一项研究提出了其调查结果cer - 0001 (tricaprilin),一个临床实验的生酮代理。结果表明,患偏头痛的人可能从治疗中获益。数据将告诉未来的研究。研究结果发表于美国头痛学会第65届社会会议,从2023年6月15日,德克萨斯州奥斯汀举行海报展示的新加坡Cerecin首席医疗官Marc Cantillon博士。推荐报告救援研究(NCT04437199)是一个双盲,随机,安慰剂对照,3个月研究tricaprilin 60克/天。主要终点是变化的基线的偏头痛天数(磁流体动力)在三个月。这不是遇到了由于缺乏统计力量,但一个有效信号在灵敏度分析指出。合格的参与者4-24磁流体动力在基线期。 Some patients chose to enter the CER-0001 compassionate access program, which allows access to tricaprilin for up to one year after completion of the clinical trial. Metabolic factors have been implicated in migraine. In patients with migraine, the brain presents an energy deficit compared to healthy subjects. Ketogenesis provides an alternative and efficient fuel source and may restore this metabolic imbalance. Some research suggests a ketogenic diet could offer some relief. Therefore, encouraging the body to enter ketosis using ketogenic drugs offers promise to sufferers of migraines. According to GlobalData , global sales for migraine drugs were valued at $4.6bn in 2020 with a compound annual growth rate of over 9%. In 2021, the US dominated the migraine market, contributing to more than 80% of the sales in the seven major pharmaceutical markets (7MM) covered – the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. A high market share in the US is attributed to the large migraine prevalent population, the costliness of branded drugs, and the number of drugs marketed exclusively in the US compared to other countries in the 7MM. Share this article